Go Pro
→ A 50-year dollar arrangement just ended - what it means for you (From Golden Portfolio) (Ad)tc pixel
NASDAQ:INVA

Innoviva Q2 2024 Earnings Report

Innoviva logo
$21.75 +0.45 (+2.09%)
As of 11:43 AM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Innoviva EPS Results

Actual EPS
$0.68
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Innoviva Revenue Results

Actual Revenue
$99.90 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Innoviva Announcement Details

Quarter
Q2 2024
Date
7/31/2024
Time
N/A
Conference Call Date
Wednesday, July 31, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Innoviva's Q2 2026 earnings is estimated for Wednesday, August 5, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, August 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Innoviva's Q2 2024 Press ReleasePress Release
(8-K)
Innoviva's Q2 2024 Quarterly reportQuarterly report
(10-Q)

Innoviva Earnings Headlines

Major Theravance Biopharma Investor Makes Notable Stock Move
July 8, 2026  |  tipranks.comhttps://www.tipranks.com/news/insider-trading/major-theravance-biopharma-investor-makes-notable-stock-move-insider-trading-news?utm_source=marketbeat.com&utm_medium=referral
Major Insider Move Rocks Theravance Biopharma Shares
July 1, 2026  |  tipranks.comhttps://www.tipranks.com/news/insider-trading/major-insider-move-rocks-theravance-biopharma-shares-insider-trading-news?utm_source=marketbeat.com&utm_medium=referral
SpaceX pays a 10X launch penalty
SpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One under $5 company's High Altitude Head Start technology could bring that down to $20,000 per launch, or $2 million across 100 missions - a 10X cost advantage. It is already flying with paying customers, but shares may not stay this cheap once Wall Street notices.tc pixel
July 28 at 1:00 AM  |  Freedom Financial (Ad)
Is Innoviva (INVA) One of the Best Cheap Small Cap Stocks to Buy Now?
July 1, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/is-innoviva-inva-one-of-the-best-cheap-small-cap-stocks-to-buy-now-1792985/
5 Cheap Small Cap Stocks to Buy Now
June 30, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/5-cheap-small-cap-stocks-to-buy-now-1791285/
Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition
June 29, 2026  |  benzinga.comhttps://www.benzinga.com/m-a/26/06/60155321/zymeworks-targets-long-term-cash-generation-through-theravance-acquisition
See More Innoviva Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Innoviva? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Innoviva and other key companies, straight to your email.

About Innoviva

Innoviva (NASDAQ:INVA), incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva’s portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.

The company was established through a spin‐out transaction in 2014, separating the royalty assets from a research‐based biopharmaceutical enterprise to create a specialized investment vehicle. Since its formation, Innoviva has supplemented its core royalty stream with additional licensing and collaboration agreements, and has pursued disciplined capital‐allocation activities to maximize dividend payments to shareholders. The firm’s contractual arrangements typically provide for tiered royalties on net sales as well as potential milestone receipts upon regulatory approvals and commercial launches.

Innoviva’s royalty revenues are generated globally through collaboration partners that market, distribute and promote the underlying therapeutics both in the United States and in international territories. The company maintains a lean corporate structure, relying on third‐party manufacturing, regulatory and commercialization expertise. Innoviva is governed by an experienced board of directors and led by management professionals with backgrounds in pharmaceutical licensing, royalty financing and capital markets.

View Innoviva Profile
Earnings Tools